The adoption of artificial intelligence in the pharmaceutical industry is transforming the way drugs are discovered, developed, and brought to market. Generative AI, in particular, is playing a crucial role in accelerating the drug discovery process, making it faster, more accurate, and cost-effective. Kimberly Powell, VP and general manager of healthcare at NVIDIA, shares her insights on how generative AI is being applied to the drug discovery process, from understanding the languages of biology and chemistry to identifying new drug candidates and optimizing the screening process. With the help of generative AI, pharmaceutical companies like Insilico Medicine are able to develop new drugs at a fraction of the cost and time, paving the way for quicker cures for diseases. This technology has the potential to revolutionize the healthcare and pharmaceutical sectors, and its impact will be felt for years to come.
Revolutionizing Drug Discovery with Generative AI
We can now take these languages … and we can apply the method of generative AI and GPT-type methods … Once we do that, the language models can really help us understand a lot more about biology that maybe we haven’t been able to observe in the real world.
1–2 minutes
TOP STORIES
Anthropic continues to engage with the Trump administration despite Pentagon tensions …
Lawmakers express concerns about AI’s rapid evolution and its risks …
OpenAI is losing key leaders as it shifts focus to enterprise AI and its superapp …
Maine’s new bill pauses large data center construction to assess environmental impacts …
Authorities arrested Daniel Moreno-Gama for attacking OpenAI CEO Sam Altman over his fears about AI …
Anthropic’s Mythos model raises national security concerns while sparking a lawsuit against the DOD …
